ABOUT SYNGENE INTERNATIONAL
Syngene International Ltd. is a publicly listed, global CRDMO headquartered in Bengaluru, India, delivering integrated discovery, development, and manufacturing services to pharmaceutical and biotech innovators. With 6,500+ employees including ~5,000 scientists and cGMP manufacturing facilities across the U.S. and India, Syngene supports 400+ active clients globally through longterm, strategic partnerships.
End-To-End CRDMO Capabilities
Syngene provides end-to-end CRDMO services across small molecules, biologics, and advanced modalities. Its capabilities span discovery through commercial manufacturing, supported by dedicated R&D centers including its flagship Bristol Myers Squibb (BMS) dedicated center. The company has built strong platforms in TIDES (peptides and oligonucleotides) and XDCs, alongside a robust small molecule and biologics backbone. Manufacturing scale includes ~50 kL biologics capacity and ~135 kL small molecule capacity, complemented by commercial fill/finish capabilities up to ~1 million via ls/da y. Integrated platforms and automation enable seamless transition from discovery to development and commercial supply.
Quality, Scale, and Sustainability
Syngene operates globally accredited, cGMP-compliant facilities with approvals from US FDA, EMA and other regulators, supporting programs for regulated markets. The company has enabled innovation through 400+ pa tents with partners and continues to scale its global delivery model. Its ESG performance is a key differentiator, with >80% renewable energy usage, zero waste to landfill, and science-based emissions reduction targets. Backed by strong governance, global partnerships, and a growing international footprint, Syngene is a trusted partner in advancing therapies from lab to market.
RESEARCH & PERSPECTIVES
-
![peptide-cdmo-GettyImages-185209542]( "Peptides: A Scientific Revolution In Modern Medicine")
GLP-1 peptides are transforming metabolic care. Discover how structural modifications extend half-lives, enable multi-receptor targeting, and expand into heart, kidney, and brain health.
-
![GettyImages-1426756188-scientists-in-lab-with-computer-analyzing]( "How Automation, Biometrics, And VR Are Redefining Quality Standards")
Modernize quality control by integrating automated workflows, digital records, and advanced training. Eliminating paper protects data integrity and accelerates regulatory timelines.
-
![bio-manufacturing-GettyImages-2194012901]( "Supply Chain Resilience In Multi-Continent Biopharma Manufacturing")
Multi-continent manufacturing networks minimize supply chain risk. Relying on site alignment, robust tech transfer, and unified quality standards ensures a flexible and resilient supply chain.
-
![GettyImages-673804426 aseptic biologics clean room lab]( "Redefining Value In Biologics Outsourcing Partnerships")
Biologics outsourcing is shifting to strategic partnerships focused on modality expertise, regulatory excellence, and integrated end-to-end capabilities.
-
![biologics-GettyImages-2149749974]( "Navigating The BIOSECURE Act Landscape")
Supply chain visibility and proactive risk strategies are vital to navigate new federal biotech restrictions and protect drug development pipelines.
VIDEOS & WEBINARS
CONTACT INFORMATION
Syngene International Ltd.
Biocon SEZ, Biocon Park, Plot.No.2 & 3, Bommasandra Indst Area IV Phase, Jigani Link Road
Bangalore, Karnataka, 560100
INDIA
Contact: Ishwarya S. Associate Director: Integrated Marketing, Ishwarya.S1@syngeneintl.com +91 8105521687
U.S. FACILITIES
Syngene International Ltd.
5901 E Lombard St.
Baltimore, MD 21224
BROCHURES
SUCCESS STORIES
-
![Pipette With Cell Culture Plate-GettyImages-520238063]( "Develop Clones In Just 9 Weeks From Transfection With Up To 4X Titer")
Transposon-based cell line development cuts timelines by 10 weeks and hits titers of 4.8 g/L in 17 days. See how SynWeave delivers measurable biologics manufacturing gains.
-
![GettyImages-824641956 monoclonal antibody]( "3X Bispecific Antibody Output, 98.5% Purity In 7 Months")
Producing bispecific antibodies at scale is notoriously difficult. See how Syngene achieved a 3X yield increase and 98.5% purity for Hinge Bio's GEM-DIMER™ platform in just seven months.
-
![Bioreactor for cell culture-GettyImages-517653054]( "Direct Scale Up From Clone To 2K GMP Batches")
N-1 perfusion technology increased antibody titers 1.5–4.5x over conventional fed-batch methods. See how high seed density and media blending cut costs and maximize suite utilization.
-
![GettyImages-1441343945-virus-viral-infection]( "Fast-Tracking NDA Approval For A Novel Compound To Treat Infections")
Strategic tech transfer and scalable manufacturing enabled rapid NDA approval, delivering registration batches and accelerating commercialization of a novel therapy for drug-resistant infections.
-
![GettyImages-2230550003 antibody receptor]( "Get Up To 4X Titer With N-1 Perfusion")
N-1 perfusion improves antibody production by increasing cell density, optimizing media and conditions, boosting yields up to 4.5× while maintaining quality and reducing manufacturing time and costs.
